Lichtenfels M, Fontana V, Nyland FH, Marques BS, Schorr MC, Marcolin JC, et al. What happens in residual disease after neoadjuvant chemotherapy? Efficacy of a novel in vitro breast cancer chemoresistance platform to demonstrate high resistance to drugs. MAST [Internet]. 2026 Mar. 12 [cited 2026 Apr. 30];33(suppl.1). Available from: https://mastology.org/journal/article/view/1539